New bladder cancer combo aims to spare patients radical surgery
NCT ID NCT04630730
Summary
This study is testing a new treatment approach for muscle-invasive bladder cancer. It combines a liquid treatment placed directly into the bladder (BCG) with standard chemotherapy and an immunotherapy drug given by IV. The main goal is to see if this combination can completely clear the cancer before surgery, which could one day help patients avoid having their bladder removed.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hôpitaux Universitaires Genève HUG
Geneva, 1211, Switzerland
-
Istituto Oncologico della Svizzera Italiana - Ospedale Regionale Bellinzona e Valli
Bellinzona, 6500, Switzerland
-
Kantonsspital Baden
Baden, 5404, Switzerland
-
Kantonsspital Graubuenden
Chur, 7000, Switzerland
-
Kantonsspital St. Gallen
Sankt Gallen, 9007, Switzerland
-
Klinik Hirslanden - Onkozentrum Hirslanden
Zurich, Canton of Zurich, 8032, Switzerland
-
Lindenhofspital
Bern, 3012, Switzerland
-
Luzerner Kantonsspital
Lucerne, 6000, Switzerland
-
UniversitaetsSpital Zuerich
Zurich, 8091, Switzerland
-
Universitaetsspital Basel
Basel, 4031, Switzerland
Conditions
Explore the condition pages connected to this study.